الولايات المتحدة · منصات وبيانات · Yahoo Finance

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell ...

نشره Yahoo Finance · الولايات المتحدة منذ 8 س

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced…

اقرأ المقال كاملًا على Yahoo Finance سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (finance.yahoo.com)

يستحق القراءة أيضًا

MarketBeat

Titan Investment Management LLC Makes New $4.43 Million Investment in Eli Lilly and Company $LLY

The Motley Fool

Elon Musk Wants to Give Every American Child a Share of SpaceX. Here's What It Would Cost -- and What It Means for Everyone Else Holding the Stock

Seeking Alpha

Musk says Ukraine violated Starlink terms with offensive drone strikes

MarketWatch

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

TheStreet

Gold prices break $4,000 as investors brace for crucial test

Benzinga